Q1 EPS Forecast for Solid Biosciences Lifted by Analyst

Solid Biosciences Inc. (NASDAQ:SLDB) – Investment analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of Solid Biosciences in a note issued to investors on Monday, March 10th. HC Wainwright analyst A. He now expects that the company will post earnings per share of ($0.43) for the quarter, up from their previous forecast of ($0.86). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($1.99) EPS, FY2027 earnings at ($1.73) EPS, FY2028 earnings at ($0.77) EPS and FY2029 earnings at $1.14 EPS.

Several other analysts also recently commented on SLDB. JMP Securities started coverage on shares of Solid Biosciences in a research report on Tuesday, December 10th. They set an “outperform” rating and a $15.00 price objective on the stock. Citizens Jmp upgraded shares of Solid Biosciences to a “strong-buy” rating in a report on Tuesday, December 10th. Truist Financial began coverage on shares of Solid Biosciences in a report on Wednesday, January 8th. They issued a “buy” rating and a $16.00 price target on the stock. Wedbush began coverage on shares of Solid Biosciences in a report on Friday, December 13th. They issued an “outperform” rating and a $16.00 price target on the stock. Finally, JPMorgan Chase & Co. reduced their price target on shares of Solid Biosciences from $12.00 to $11.00 and set an “overweight” rating on the stock in a report on Thursday. Nine investment analysts have rated the stock with a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, Solid Biosciences has an average rating of “Buy” and a consensus price target of $15.70.

Solid Biosciences Price Performance

Shares of SLDB stock opened at $5.14 on Wednesday. The company has a market capitalization of $398.31 million, a price-to-earnings ratio of -1.69 and a beta of 1.98. Solid Biosciences has a one year low of $2.88 and a one year high of $15.05. The company’s fifty day moving average price is $4.15 and its 200-day moving average price is $5.47.

Institutional Trading of Solid Biosciences

A number of large investors have recently made changes to their positions in SLDB. Los Angeles Capital Management LLC bought a new stake in shares of Solid Biosciences in the 3rd quarter worth about $293,000. Valence8 US LP bought a new stake in shares of Solid Biosciences in the 3rd quarter worth about $110,000. The Manufacturers Life Insurance Company bought a new position in Solid Biosciences during the 3rd quarter valued at about $71,000. FMR LLC bought a new position in Solid Biosciences during the 3rd quarter valued at about $305,000. Finally, MetLife Investment Management LLC grew its holdings in Solid Biosciences by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 13,699 shares of the company’s stock valued at $95,000 after purchasing an additional 7,719 shares during the last quarter. 81.46% of the stock is currently owned by institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.